Exceptional responder
ER/PR-positive, adenopathy, high-grade TNBC
DISEASE, MAY, ADENOPATHY, RESIDUAL DISEASE, PATHOLOGY, HER2-NEGATIVE BREAST CANCER
Patient was initially diagnosed with ER/PR-positive, HER2-negative breast cancer in 2002. She was treated with surgery, adjuvant cyclophosphamide methotrexate fluorouracil (CMF), and radiation therapy, followed by 5 years of adjuvant tamoxifen. In 2011, patient who recurred with high-grade TNBC received neoadjuvant docetaxel and cyclophosphamide, followed by bilateral mastectomy. Surgical pathology demonstrated yPT2N1 residual disease. Patient further received adjuvant gemcitabine and cisplatin and then had progressive disease with adenopathy in the axilla and mediastinum. Patient received the following lines of therapy: first-line carboplatin and paclitaxel from September 2015 to December 2016; second-line Xeloda from January 2017 to April 2017; third-line doxorubicin; and 22 cycles pembrolizumab from May 2017 to July 2018. Patient had an exceptional response but progressed on study.